Literature DB >> 11884942

CD4+ T cells initiate pancreatic islet xenograft rejection via an interferon-gamma-dependent recruitment of macrophages and natural killer cells.

Shounan Yi1, Ximin Feng, Wayne J Hawthorne, Anita T Patel, Stacey N Walters, Philip J O'Connell.   

Abstract

BACKGROUND: In this study, the mechanisms by which CD4+ T cells interact with the innate immune system in xenograft rejection were investigated.
METHODS: Fetal pig pancreas (FPP) grafts were transplanted into female SCID mice. The FPP recipient SCID mice were reconstituted with exogenous leukocytes obtained from male BALB/c mice.
RESULTS: Although nonreconstituted SCID recipients or recipients reconstituted with CD4+ T cell-depleted leukocytes showed indefinite FPP graft survival with very few macrophages infiltrating their grafts, reconstitution of SCID recipients with as few as 2x10(5) CD4+ T cells was sufficient to induce rapid xenograft rejection. CD4+ T cells secreted interferon-gamma but not interleukin-4 and initiated the activation and accumulation of macrophages and natural killer cells, that were responsible for the rapid graft destruction. Suppression of interferon-gamma prolonged graft survival and suppressed the macrophages and natural killer cell accumulation and activation.
CONCLUSIONS: These results demonstrate that CD4+ T cell-dependent cellular xenograft rejection was a result of macrophage and natural killer cell accumulation and activation, but was not mediated by eosinophils. Consistent with this was the finding that interferon-gamma but not interleukin-4 was in part responsible for mediating this effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884942     DOI: 10.1097/00007890-200202150-00019

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

Review 1.  Transplantation of xenogeneic islets: are we there yet?

Authors:  Philip J O'Connell; Peter J Cowan; Wayne J Hawthorne; Shounan Yi; Andrew M Lew
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

Review 2.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

3.  Differential Role of B Cells and IL-17 Versus IFN-γ During Early and Late Rejection of Pig Islet Xenografts in Mice.

Authors:  Hee Kap Kang; Shusen Wang; Anil Dangi; Xiaomin Zhang; Amar Singh; Lei Zhang; James M Rosati; Wilma Suarez-Pinzon; Xuelian Deng; Xiaoyan Chen; Edward B Thorp; Bernhard J Hering; Stephen D Miller; Xunrong Luo
Journal:  Transplantation       Date:  2017-08       Impact factor: 4.939

4.  CD4 T cells mediate cardiac xenograft rejection via host MHC Class II.

Authors:  Robert J Plenter; Todd J Grazia; An N Doan; Ronald G Gill; Biagio A Pietra
Journal:  J Heart Lung Transplant       Date:  2012-07-11       Impact factor: 10.247

Review 5.  Progress in xenotransplantation: overcoming immune barriers.

Authors:  Megan Sykes; David H Sachs
Journal:  Nat Rev Nephrol       Date:  2022-10-05       Impact factor: 42.439

6.  Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents.

Authors:  C Gysemans; K Stoffels; A Giulietti; L Overbergh; M Waer; M Lannoo; U Feige; C Mathieu
Journal:  Diabetologia       Date:  2003-07-17       Impact factor: 10.122

Review 7.  Xenotransplantation: immunological hurdles and progress toward tolerance.

Authors:  Adam Griesemer; Kazuhiko Yamada; Megan Sykes
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

8.  Th1-Dominant CD4+ T Cells Orchestrate Endogenous Systematic Antitumor Immune Memory After Cryo-Thermal Therapy.

Authors:  Peng Peng; Yue Lou; Junjun Wang; Shicheng Wang; Ping Liu; Lisa X Xu
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

Review 9.  Cellular Immune Responses in Islet Xenograft Rejection.

Authors:  Min Hu; Wayne J Hawthorne; Shounan Yi; Philip J O'Connell
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.